Stat Med. 2025 Feb 28;44(5):e70001. doi: 10.1002/sim.70001.
ABSTRACT
A surrogate marker is a biological measurement in a clinical trial that aims to replace the primary outcome in evaluating the treatment effect, and can be measured earlier, with less cost, or with less patient burden. In theory, once a surrogate is validated, future studies can evaluate treatment efficacy using only the surrogate. While there are many methods to evaluate a surrogate, these methods rarely account for heterogeneity in surrogacy, that is, when a surrogate is valid for only certain people. We propose a general framework for the assessment of complex heterogeneity in the strength of a surrogate marker, as well as corresponding parametric and semiparametric estimation procedures. Our framework defines the proportion of the treatment effect on the primary outcome that is explained by the treatment effect on the surrogate, as a function of multiple baseline covariates, W $$ mathbf{W} $$ . We additionally propose a formal test of heterogeneity and a method to identify a region of the covariate space where the surrogate is sufficiently strong. We examine the performance of our methods via a simulation study featuring varying levels of heterogeneity and use our methods to examine potential heterogeneity in the strength of a surrogate in an AIDS clinical trial.
PMID:39915898 | DOI:10.1002/sim.70001
